|
イワモト タカユキ
Takayuki Iwamoto
岩本 高行 所属 川崎医科大学 医学部 臨床医学 乳腺甲状腺外科学 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. |
| 掲載誌名 | 正式名：Journal of clinical oncology : official journal of the American Society of Clinical Oncology 略 称：J Clin Oncol ISSNコード：15277755/0732183X |
| 掲載区分 | 国外 |
| 巻・号・頁 | 28(28),pp.4316-23 |
| 著者・共著者 | Giampaolo Bianchini, Yuan Qi, Ricardo H Alvarez, Takayuki Iwamoto, Charles Coutant, Nuhad K Ibrahim, Vicente Valero, Massimo Cristofanilli, Marjorie C Green, Laszlo Radvanyi, Christos Hatzis, Gabriel N Hortobagyi, Fabrice Andre, Luca Gianni, W Fraser Symmans, Lajos Pusztai |
| 発行年月 | 2010/10 |
| 概要 | PURPOSE:The purpose of this study was to identify genes enriched in breast cancer stroma, assess the stromal gene expression differences between estrogen receptor (ER) -positive and -negative cancers, and separately determine their prognostic value in these two subtypes of breast cancers.METHODS:We compared gene expression profiles of pairs of fine-needle (stroma-poor) and core-needle (stroma-rich) biopsies from 37 cancers to identify stroma-associated genes. We defined stromal metagenes and tested their prognostic values in 684 node-negative patients who received no systemic adjuvant therapy and 259 tamoxifen-treated patients.RESULTS:We identified 293 probe sets overexpressed in core biopsies; these included five highly coexpressed gene clusters (metagenes) corresponding to immune functions and extracellular matrix components. These genes showed quantitative and qualitative differences between ER-positive and ER-negative cancers. A B-cell/plasma cell metagene showed strong prognostic value in ER-positive highly proliferative cancers, a lesser prognostic value in ER-negative cancers, and no prognostic value in ER-positive cancers with low proliferation. The hazard ratio for distant relapse in the lowest compared with the highest tertile of the pooled prognostic data set was 4.29 (95% CI, 2.04 to 9.01; P = .001) in ER-positive cancers and 3.34 (95% CI, 1.60 to 6.97; P = .001) in ER-negative cancers. This remained significant in multivariate analysis including routine variables and other genomic prognostic scores. As a result of quantitative differences in this metagene between ER-positive and ER-negative cancers, different thresholds apply in the two subgroups. Other stromal metagenes had inconsistent prognostic value.CONCLUSION:Among ER-negative and ER-positive highly proliferative cancers, a subset of tumors with high expression of a B-cell/plasma cell metagene carries a favorable prognosis. |
| DOI | 10.1200/JCO.2009.27.2419 |
| PMID | 20805453 |